Exploratory Evaluation of Rhythm Control by Dronedarone in Combination With Low-Dose Rivaroxaban, Warfarin, Antiplatelet, or None of the Antithrombotic Therapy in High-Risk Patients With Non-Permanent Atrial Fibrillation: A Retrospective Cohort Study

The emerging data supports rhythm control to prevent major adverse cardiac events (MACE) in high-risk patients with atrial fibrillation (AF). Limited data demonstrated rivaroxaban 10 mg combining dronedarone seemed feasible. This study aimed at investigating clinical events in a dronedarone-treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Po-Lin, Chiou, Wei-Ru, Su, Min-I, Huang, Chun-Che, Liao, Feng-Ching, Liu, Lawrence Yu-Min, Chuang, Jen-Yu, Chen, Chun-Yen, Tsai, Cheng-Ting, Kuo, Jen-Yuan, Yang, Ten-Fang, Wu, Yih-Jer, Lee, Ying-Hsiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671665/
https://www.ncbi.nlm.nih.gov/pubmed/34894780
http://dx.doi.org/10.1177/10760296211052968

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671665/
https://www.ncbi.nlm.nih.gov/pubmed/34894780
http://dx.doi.org/10.1177/10760296211052968

Ejemplares similares